Summary

Guide-Line of the Radio-Iodine ($^{131}$I) Therapy in Graves’ Disease and Thyroid Cancer

Yutaka MORI*1, Kiyoko KUSAKABE*2, Katsuji IKEKUBO*3, Naofumi ISHIKAWA*4, Kunihiro NAKADA*5, Shinichi KANAYA*2, Takashi MISAKI*6, Kunihiko YOKOYAMA*7, Atsushi KUBO*8, Tatsuya HIGASHI*9, Kouichi ITO*4, Yasushi NOGUCHI*10, Shinsaku TSUCHIMOCHI*11 and Takashi TOGAWA*12

*1 Department of Radiology, The Jikei University School of Medicine
*2 Department of Radiology, Tokyo Women’s Medical University
*3 Hyogo Health Service Association
*4 Department of Internal Medicine, Ito Hospital
*5 Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine
*6 Tenri Hospital
*7 Department of Nuclear Medicine, Kanazawa University Graduate School of Medicine
*8 Department of Radiology, School of Medicine, Keio University
*9 Department of Nuclear Medicine, Kyoto University Graduate School of Medicine
*10 Noguchi Hospital
*11 Department of Radiology, Kagoshima University Graduate School of Medicine
*12 Division of Nuclear Medicine, Chiba Cancer Center

Radio-iodine ($^{131}$I) therapy has been using in Graves’ disease and well differentiated thyroid cancer. The rules of control in the discharge from radio-isotope hospital were notified in 1999 in Japan. Guide-line of the $^{131}$I therapy in Graves’ disease and thyroid cancer were prepared by sub-group of Japanese Society of Nuclear Medicine. 

Key words: Graves’ disease, Hyperthyroidism, Thyroid cancer, Radio-iodine therapy, Japanese guide-line.